Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

Prior treatment

• Systemic antineoplastic therapy (except adjuvant therapies) received prior to AI and CDK4/6i;
• Prior exposure to camizestrant, other SERD or investigational endocrine therapy agents;
• Patients relapsing while on or during the year after the discontinuation of adjuvant CDK4/6 inhibitor.
• Participation in another clinical study whose procedures interfere with those of the study (within 28 days prior to participant enrolment and for the duration of the study);
• Participants with synchronous disease progression per local assessment (tumor imaging performed within 28 days prior to entry in Step #2 RECIST v1.1);
• Participants treated within the last 2 weeks before randomization with medications that are sensitive substrates (e.g. omeprazole) or substrates with narrow therapeutic index of CYP2C9 and/or CYP2C19 (e.g. warfarin and phenytoin). Strong CYP3A4/5 inducers should be stopped at least 2 weeks before randomization (3 weeks for St John's Wort).

Other illness

• History of bone marrow transplantation;
• Participants presenting any cardiovascular conditions (as described in the protocol)
• Participant with a known active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), HBV (known positive HBsAg result), and HCV. Participants with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antigen \[HBsAg\] test and a positive hepatitis B core antibody \[HBcAb\] test, accompanied by a negative HBV DNA test) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA

Lab values

• Participant who was treated within the timeframe indicated in the CSP with drugs that are known to prolong the QT interval.
• Participant taking medications known to prolong the QT interval and associated with a known risk of Torsades de Pointes
• Participants known to be positive for HIV can be enrolled if they fulfil the criteria recommended by Food and Drug Administration (FDA) and ASCO guidelines (FDA Guidance, Uldrick et al 2017): CD4+ T-cell (CD4+) counts ≥350 cells/µL, AND No history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months (prophylactic antimicrobials allowed if no DDI or overlapping toxicities), AND On established anti-retroviral therapy (ART) for at least 4 weeks and have an HIV viral load less than 400 copies/mL before enrolment. Effective ART is defined as a drug, dosage and schedule associated with reduction and control of the viral load

Age

• History of another malignancy, except (i) those treated with curative intent and with no known active disease ≥3 years; (ii) adequately treated non-melanoma cutaneous and in-situ cervix cancer;

Other

• Related to step #1:
• Known leptomeningeal metastasis and/or brain metastasis;
• Known contraindication to camizestrant and abemaciclib, per investigator assessment;
• Pregnant women or women who are breast-feeding or participants not willing to apply highly effective contraception as defined in the protocol;
• Participants unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons;
• Persons deprived of their liberty or under protective custody or guardianship;
  • Related to step #2:
• Participants with a contraindication to abemaciclib, as assessed by the investigator;

• Related to Step #1
• First written informed consent (ICF#1) prior to any trial specific procedures. When the participant is physically unable to give his written consent, an impartial witness, independent from the investigator and the sponsor, can confirm in signing the participant's consent;
• Men or women ≥ 18 years of age;
• Eastern Cooperative Oncology Group performance status of 0 or 1;
• ER+ HER2- advanced (metastatic or locally advanced inoperable) breast adenocarcinoma (ER-positivity threshold: ≥10% tumor cells; HER2-negative tumour is defined as an immunohistochemical (IHC) score of 0 or 1+, or an IHC score of 2+ with negative in situ hybridization (ISH) (HER2/CEP17 ratio \<2 or, for single probe assessment, HER2 copy number \<4, according to the most recent available results), not amenable to resection or radiation therapy with curative intent;
• Eligible to (per investigator assessment) or currently receiving for up to 3 years, AI (+/- LH-RH agonist) and CDK4/6i (palbociclib or ribociclib) as first line therapy with adequate cardiac, renal, hematological and hepatic functions per investigator assessment;
• Evaluable disease (RECIST v1.1) before the start of AI+CDK4/6i and, in participants currently receiving AI and CDK4/6i, no evidence of clinical or radiological progression since AI+CDK4/6i initiation;
• Must have an adequate archival tumor tissue sample available (with a cellularity \> 30%) for centralized WGS analysis to design the ctDNA test. Requirements:
• Pre/perimenopausal women and fertile men must agree to use adequate contraception methods during the study:
  • Female participants must be using highly effective standard-of-care non-hormonal contraceptive measures from the time of screening until 3 weeks after exiting from Step #1 (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly); or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: (a) Post-menopausal, defined as women with: (i) Cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; (ii) Cessation of regular menses for at least 6 consecutive months with no alternative pathological or physiological cause AND with serum estradiol and follicle stimulating hormone level within the laboratory's reference range for post-menopausal females; (iii) Previous bilateral surgical oophorectomy.
  • Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using an acceptable method of contraception until at least one week after the last treatment administration.
• Women of childbearing potential must have a negative serum or urine pregnancy test done within 28 days before inclusion;
• Minimum life expectancy of at least 6 months;
• Participants must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan and other study procedures including follow-up;
• Participants must be affiliated with a social security scheme or a beneficiary of such a scheme (or equivalent);
  • Additional criteria to be part of the imaging de-escalation sub-study in Step #1:
• Additional written informed consent (ICF#2). When the participant is physically unable to give his written consent, an impartial witness, independent from the investigator and the sponsor, can confirm in signing the participant's consent;
• Participants must have received at least 6 months (from 22 weeks authorized) of treatment with AI + CDK4/6 inhibitor, with no evidence of ctDNA rising in STEP #1 (at the current visit or, if current results are pending, at the previous visit), and no disease progression on imaging at the current visit as per RECIST v1.1.
• ctDNA detected at study entry and no rising ctDNA;
• No history of venous thrombo-embolic event, interstitial lung disease or any pre-existing condition that may impair participant's respiratory function (per investigator assessment);
• Willingness and ability to comply with scheduled visits;
  • Related to Step #2:
• Additional written informed consent (ICF#3). When the participant is physically unable to give his written consent, an impartial witness independent from the investigator and the sponsor, can confirm in signing the participant's consent;
• Rising ctDNA (as defined in the protocol) detected during Step #1 (centrally determined);
• Having received at least 6 months of AI + CDK4/6i;
• Adequate bone marrow reserve and organ function as follows:
  • Hemoglobin ≥9.0g/dL (90 g/L).
  • Absolute neutrophil count ≥1000/mm3 (1.0×10\^9/L) or documented institutional normal range for starting abemaciclib.
  • Total bilirubin ≤1.5×ULN or ≤3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia).
  • ALT and AST ≤3×ULN; for participants with hepatic metastases, ALT and AST ≤5×ULN.
  • Alkaline phosphatase ≤2.5×ULN (≤ 5.0×ULN if bone or liver metastases present).
  • Serum creatinine ≤ 1.5×ULN or calculated creatinine clearance ≥ 30 mL/min as determined by Cockcroft-Gault (using actual body weight).
• Female participants must have a negative highly sensitive serum pregnancy test during the screening period if they are of childbearing potential and agree to use highly effective contraceptive methods to prevent pregnancy during the study and for 4 weeks following the last dose of camizestrant (if applicable) and/or for 3 weeks after the last dose of CDK4/6inhibitor or must have evidence of nonchildbearing potential. In addition, female participants must refrain from egg cell donation and breastfeeding during this same period.
  • Non-sterilized male partners of a participant who is a woman of childbearing potential must use a male condom plus spermicide from the time of screening throughout the total duration of the study until 4 weeks after last dose of camizestrant.
  • Non-sterilised male participants (including males sterilised by a method other than bilateral orchidectomy, eg, vasectomy) who intend to be sexually active with a Female Of ChildBearing Potential (FOCBP) must be using an acceptable method of contraception, such as male condom plus spermicide (condom alone in countries where spermicides are not approved), from enrolment throughout the study until at least 1 week to avoid conception during treatment. Male participants must not donate or bank sperm during this same period.
  • Female partners (of child-bearing potential) of male participants enrolled in this study must also use a highly effective method of contraception from the time of study enrolment of their male partner, throughout their participation in the study, and until at least 1 week after their male partners last dose of camizestrant.